Eintrag weiter verarbeiten
Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews”
Gespeichert in:
| Zeitschriftentitel: | Clinical Pharmacology & Therapeutics |
|---|---|
| Personen und Körperschaften: | , , |
| In: | Clinical Pharmacology & Therapeutics, 102, 2017, 1, S. 21-24 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Castellini, G Nielsen, EE Gluud, C Castellini, G Nielsen, EE Gluud, C |
|---|---|
| author |
Castellini, G Nielsen, EE Gluud, C |
| spellingShingle |
Castellini, G Nielsen, EE Gluud, C Clinical Pharmacology & Therapeutics Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” Pharmacology (medical) Pharmacology |
| author_sort |
castellini, g |
| spelling |
Castellini, G Nielsen, EE Gluud, C 0009-9236 1532-6535 Wiley Pharmacology (medical) Pharmacology http://dx.doi.org/10.1002/cpt.536 <jats:p>Trial Sequential Analysis (TSA) is a frequentist method to help researchers control the risks of random errors in meta‐analyses.<jats:sup>1</jats:sup> Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup> used TSA on cell therapy for heart diseases. The present article discusses the usefulness of TSA and its dependence on the choice of the parameters for calculation of the required information size and the adjacent monitoring boundaries, and comments on the approach by Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup></jats:p> Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” Clinical Pharmacology & Therapeutics |
| doi_str_mv |
10.1002/cpt.536 |
| facet_avail |
Online |
| finc_class_facet |
Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jcHQuNTM2 |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jcHQuNTM2 |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
Wiley, 2017 |
| imprint_str_mv |
Wiley, 2017 |
| issn |
0009-9236 1532-6535 |
| issn_str_mv |
0009-9236 1532-6535 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
castellini2017commentoncelltherapyforheartdiseasetrialsequentialanalysesoftwocochranereviews |
| publishDateSort |
2017 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Pharmacology & Therapeutics |
| source_id |
49 |
| title |
Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_unstemmed |
Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_full |
Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_fullStr |
Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_full_unstemmed |
Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_short |
Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_sort |
comment on: “cell therapy for heart disease: trial sequential analyses of two cochrane reviews” |
| topic |
Pharmacology (medical) Pharmacology |
| url |
http://dx.doi.org/10.1002/cpt.536 |
| publishDate |
2017 |
| physical |
21-24 |
| description |
<jats:p>Trial Sequential Analysis (TSA) is a frequentist method to help researchers control the risks of random errors in meta‐analyses.<jats:sup>1</jats:sup> Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup> used TSA on cell therapy for heart diseases. The present article discusses the usefulness of TSA and its dependence on the choice of the parameters for calculation of the required information size and the adjacent monitoring boundaries, and comments on the approach by Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup></jats:p> |
| container_issue |
1 |
| container_start_page |
21 |
| container_title |
Clinical Pharmacology & Therapeutics |
| container_volume |
102 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792337905635557382 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T15:23:19.42Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Comment+on%3A+%E2%80%9CCell+therapy+for+heart+disease%3A+Trial+sequential+analyses+of+two+cochrane+reviews%E2%80%9D&rft.date=2017-07-01&genre=article&issn=1532-6535&volume=102&issue=1&spage=21&epage=24&pages=21-24&jtitle=Clinical+Pharmacology+%26+Therapeutics&atitle=Comment+on%3A+%E2%80%9CCell+therapy+for+heart+disease%3A+Trial+sequential+analyses+of+two+cochrane+reviews%E2%80%9D&aulast=Gluud&aufirst=C&rft_id=info%3Adoi%2F10.1002%2Fcpt.536&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792337905635557382 |
| author | Castellini, G, Nielsen, EE, Gluud, C |
| author_facet | Castellini, G, Nielsen, EE, Gluud, C, Castellini, G, Nielsen, EE, Gluud, C |
| author_sort | castellini, g |
| container_issue | 1 |
| container_start_page | 21 |
| container_title | Clinical Pharmacology & Therapeutics |
| container_volume | 102 |
| description | <jats:p>Trial Sequential Analysis (TSA) is a frequentist method to help researchers control the risks of random errors in meta‐analyses.<jats:sup>1</jats:sup> Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup> used TSA on cell therapy for heart diseases. The present article discusses the usefulness of TSA and its dependence on the choice of the parameters for calculation of the required information size and the adjacent monitoring boundaries, and comments on the approach by Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup></jats:p> |
| doi_str_mv | 10.1002/cpt.536 |
| facet_avail | Online |
| finc_class_facet | Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTAwMi9jcHQuNTM2 |
| imprint | Wiley, 2017 |
| imprint_str_mv | Wiley, 2017 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0009-9236, 1532-6535 |
| issn_str_mv | 0009-9236, 1532-6535 |
| language | English |
| last_indexed | 2024-03-01T15:23:19.42Z |
| match_str | castellini2017commentoncelltherapyforheartdiseasetrialsequentialanalysesoftwocochranereviews |
| mega_collection | Wiley (CrossRef) |
| physical | 21-24 |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Clinical Pharmacology & Therapeutics |
| source_id | 49 |
| spelling | Castellini, G Nielsen, EE Gluud, C 0009-9236 1532-6535 Wiley Pharmacology (medical) Pharmacology http://dx.doi.org/10.1002/cpt.536 <jats:p>Trial Sequential Analysis (TSA) is a frequentist method to help researchers control the risks of random errors in meta‐analyses.<jats:sup>1</jats:sup> Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup> used TSA on cell therapy for heart diseases. The present article discusses the usefulness of TSA and its dependence on the choice of the parameters for calculation of the required information size and the adjacent monitoring boundaries, and comments on the approach by Fisher <jats:italic>et al</jats:italic>.<jats:sup>2</jats:sup></jats:p> Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” Clinical Pharmacology & Therapeutics |
| spellingShingle | Castellini, G, Nielsen, EE, Gluud, C, Clinical Pharmacology & Therapeutics, Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews”, Pharmacology (medical), Pharmacology |
| title | Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_full | Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_fullStr | Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_full_unstemmed | Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_short | Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| title_sort | comment on: “cell therapy for heart disease: trial sequential analyses of two cochrane reviews” |
| title_unstemmed | Comment on: “Cell therapy for heart disease: Trial sequential analyses of two cochrane reviews” |
| topic | Pharmacology (medical), Pharmacology |
| url | http://dx.doi.org/10.1002/cpt.536 |